Business Wire

CREDIT SUISSE AT1s: Pallas Partners forming Investor Group

21.3.2023 20:03:00 EET | Business Wire | Press release

Share

 

Overview

Pallas Partners LLP (“Pallas”) is building a group of holders of Credit Suisse’s Additional Tier 1 Bonds (“AT1s”) wiped out at the weekend as part of the Swiss government-mandated takeover of Credit Suisse by UBS. The group will pursue a multi-faceted litigation strategy to seek to mitigate losses suffered by holders of the AT1s and allow recoveries to be made, through focused litigation against those who have acted to deprive the AT1s of their contractual and other rights.

Pallas is holding an investor call at 4pm UK / 12pm NY on Wednesday 22 March 2023 to discuss the group and the litigation strategy. Please email CSAT1Investors@pallasllp.com for details on how to join the call.

The Investor Group

Since events over the weekend by which the Swiss government and regulators forced through a takeover of Credit Suisse by UBS, a term of which was to write down the AT1s to zero, Pallas has been working with AT1 holders and investors to explore options to recover losses and understand the value play through litigation.

Pallas and investors are focused on the actions of the Swiss authorities (FINMA, the Federal Council and others) to pass through last-minute legislation purportedly providing for this AT1 wipe-out which upended the established claims hierarchy allowing equity holders to remain in the structure to the detriment of the AT1s.

We are exploring a cohesive multi-jurisdictional strategy to be pursued by a cohesive group of international investors in the AT1s, to recover losses.

Investors will be eligible to join the investor group if they held AT1s as at 17 March 2023, or hold AT1s at present. There is no jurisdictional restriction.

The Litigation Strategy

In extraordinary circumstances such as these, it is imperative that investors work together to pursue a litigation strategy designed to litigate against the right defendants in the right jurisdictions. A fractured investor community, spending time litigating in the wrong places against the wrong defendants will not serve the interests of the AT1s, and will not drive recoveries for AT1 holders.

Pallas is therefore building out a litigation strategy which considers both local law remedies and also remedies outside of Switzerland given the international nature of investors and the places in which statements were made to the market regarding CS’ liquidity and solvency position.

Details of the proposed recoveries strategy will be shared on the call, and Pallas can provide more detailed advice once an investor is a member of the group (and subject to confirmation of AT1 holdings).

Investor Call

Pallas’ investor group will take place at 4pm UK / 12pm NY on Wednesday 22 March 2023.

Details of the call are available from CSAT1Investors@pallasllp.com.

About Pallas Partners

Pallas Partners is a London and New York elite litigation firm specialising in high stakes litigation, international arbitration and investigations at the very top end of the market, for the world’s most sophisticated clients. The firm litigates cutting edge and complex cases, including securities litigation in the UK and Europe.

Pallas and its lawyers have an extraordinary depth of experience in litigating matters relating to bank resolutions, bank wind-downs, government interventions and CoCo redemptions and cancellations. We have acted on bank and investor challenges in Iceland, Ireland, UK, Cyprus, Greece, Spain, Portugal, Austria and Ukraine, and have represented holders of CoCo bonds in challenging cancellations and early redemptions, through to the UK Supreme Court.

Pallas is currently representing lenders to Mozambican SPVs in the “tuna bond” litigation against, amongst others, Credit Suisse, before the English Courts. We are also representing Greensill investors with respect to claims against Credit Suisse. Pallas also has an extensive practice acting for special situations and distressed holders in designing and implementing litigation strategies to recover value and create leverage.

Pallas’ Managing Partner Natasha Harrison is leading this mandate. Natasha is one of the leading litigators of the most important investor disputes of the last decade. Natasha is top-ranked in Legal 500 and Chambers & Partners, and is described as a “leading banking litigator” in those publications. Super Lawyers and Lawdragon have named her as a leading commercial litigator and Who’s Who named her as a Restructuring Thought Leader for 2022. In 2021 she won Legal Advisor of the Year at the Women in Finance Awards, she was shortlisted for a Lifetime Achievement Award by the Law Society and for Managing Partner of the Year by Legal Business. She was also listed by Financial News as one of the 50 Most Influential Lawyers in 2022 and as one of the 100 Most Influential Women in European Finance in 2022.

The wider team includes Duane Loft in New York, Fiona Huntriss, Tracey Dovaston and Neil Pigott in London, all of whom have deep experience in these issues.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information


Media:
Camarco
Ed Gascoigne-Pees, Partner
Julia Tilley, Partner
+44 (0)7815 068 387

Investors:
Natasha Harrison: nharrison@pallasllp.com
Pallas AT1 team: CSAT1@pallasllp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release

Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development

Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye